---
title: "DYN.US (DYN.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DYN.US/news.md"
symbol: "DYN.US"
name: "DYN.US"
parent: "https://longbridge.com/en/quote/DYN.US.md"
datetime: "2026-05-20T06:51:50.382Z"
locales:
  - [en](https://longbridge.com/en/quote/DYN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DYN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DYN.US/news.md)
---

# DYN.US (DYN.US) — Related News

### [Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares](https://longbridge.com/en/news/286950631.md)
*2026-05-19T17:45:18.000Z*
> Saturn V Capital Management sold 822,007 shares of Dyne Therapeutics for approximately $14.17 million, reducing its stak

### [Assessing Dyne Therapeutics (DYN) Valuation After Recent Pullback And Contrasting P/B And DCF Signals](https://longbridge.com/en/news/286700774.md)
*2026-05-18T02:09:35.000Z*
> Dyne Therapeutics (DYN) has experienced a recent pullback, closing at $17.29, with a mixed performance over various time

### [Dyne Therapeutics (DYN) Gets a Buy from LifeSci Capital](https://longbridge.com/en/news/286648971.md)
*2026-05-16T14:36:16.000Z*
> LifeSci Capital analyst Francois Brisebois has maintained a Buy rating on Dyne Therapeutics (DYN) with a price target of

### [Dyne Therapeutics (NASDAQ:DYN) Upgraded at Wall Street Zen](https://longbridge.com/en/news/286634683.md)
*2026-05-16T05:30:46.000Z*
> Wall Street Zen upgraded Dyne Therapeutics (NASDAQ:DYN) from a 'strong sell' to a 'sell' rating. Other analysts have var

### [Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 3,311 Shares](https://longbridge.com/en/news/286472443.md)
*2026-05-14T21:33:45.000Z*
> Dyne Therapeutics CEO John Cox sold 3,311 shares at $18.36 each, totaling $60,789.96, to cover tax obligations from equi

### [HC Wainwright Has Optimistic Outlook of DYN Q2 Earnings](https://longbridge.com/en/news/286408522.md)
*2026-05-14T11:29:55.000Z*
> HC Wainwright has raised its Q2 2026 EPS estimate for Dyne Therapeutics (NASDAQ:DYN) from ($0.76) to ($0.68) per share, 

### [Dyne Therapeutics to Participate in Upcoming Investor Conferences](https://longbridge.com/en/news/286254825.md)
*2026-05-13T11:31:39.000Z*
> In Waltham, Massachusetts, on May 13, 2026, Dyne Therapeutics, Inc. (Nasdaq: DYN), which specializes in developing treat

### [Dyne Therapeutics (NASDAQ:DYN) Announces Earnings Results](https://longbridge.com/en/news/285972848.md)
*2026-05-11T16:20:42.000Z*
> Dyne Therapeutics (NASDAQ:DYN) announced its quarterly earnings, reporting an EPS of ($0.73), surpassing estimates of ($